文献速递膀胱癌与上尿路尿路上皮癌

小细胞变异型尿路上皮癌具有高肿瘤突变负荷及TP53/RB突变

Urothelial Cancers with Small Cell Variant Histology Have Confirmed High Tumor Mutational Burden, Frequent TP53 and RB Mutations, and a Unique Gene Expression Profile.
PubMed 文献 · Eur Urol Oncol · 2020-02-13

该研究基于Foundation Medicine数据库2012年6月至2018年9月的数据,分析了3368例膀胱癌/上尿路尿路上皮癌(BC/UTUC)样本,其中3.92%(132例)具有小细胞/神经内分泌特征。这些样本中TP53突变占92%、RB1突变占75%、TP53/RB1共突变占72%、TERT启动子突变占68%,6.5%的样本TMB≥10突变/Mb。RNA表达谱分析显示,与尿路上皮膀胱癌相比,小细胞膀胱癌(SCBC)有大量差异表达基因,且多个炎症通路受抑制。

要点

  • 小细胞/神经内分泌特征在BC/UTUC中占3.92%,TP53和RB1突变频率高。
  • 6.5%的小细胞变异样本TMB≥10突变/Mb,支持高肿瘤突变负荷。
  • SCBC表达谱与尿路上皮膀胱癌显著不同,炎症通路受抑制。

核心结论

  • SCBC具有与SCLC相似的突变特征(TP53/RB1富集)和独特基因表达谱,可能解释其侵袭性表型。

研究设计与样本

  • 回顾性分析Foundation Medicine数据库2012年6月至2018年9月的3368例BC/UTUC样本,其中132例(3.92%)具有小细胞/神经内分泌特征。
  • 另取独立队列24例纯SCBC和51例肌层浸润性尿路上皮膀胱癌(UBC)样本进行RNA表达谱分析。

主要发现

  • 132例小细胞/神经内分泌特征样本中,TP53突变92%、RB1突变75%、TP53/RB1共突变72%、TERT启动子突变68%。
  • 6.5%的样本TMB≥10突变/Mb。
  • SCBC与UBC之间存在大量差异表达基因,SCBC中多个炎症通路受抑制。

临床怎么用

  • 对BC/UTUC小细胞变异患者,可考虑检测TP53/RB1突变状态及TMB,辅助风险分层。
  • SCBC的独特表达谱提示其可能对免疫治疗反应不同,需进一步临床研究验证。

局限性

  • 研究为回顾性数据库分析,样本选择可能存在偏倚。
  • RNA表达谱分析样本量较小(24例SCBC和51例UBC)。
  • 未报告临床预后数据与基因组特征的关联。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Although predominantly urothelial, some bladder cancer and upper tract urothelial cancer (BC/UTUC) harbor histologic variants. Small cell BC (SCBC) variants comprised ˜5% of The Cancer Genome Atlas BC cohort, with a poor prognosis. We describe genomic profiles of BC/UTUC with small cell/neuroendocrine features identified in the Foundation Medicine database from June 2012 to September 2018. Of 3368 BC/UTUC samples, 3.92% (132) harbored small cell/neuroendocrine features by immunohistochemistry. Mutations were noted in: TP53 (92%), RB1 (75%), combined TP53/RB1 (72%), and TERT promoter (68%). Of the samples, 6.5% had TMB ≥ 10 mutations/Mb. RNA expression profiling of 24 pure SCBC and 51 urothelial BC (UBC) muscle-invasive samples evaluated from a separate cohort revealed a large number of differentially expressed genes with suppression of several inflammatory pathways in SCBC compared with UBC. This largest reported SCBC dataset to date confirms enrichment of signatures in SCBC similar to small cell lung cancer and describes unique gene expression compared with UBC. These findings may explain aggressive SCBC phenotype. PATIENT SUMMARY: Small cell bladder cancer (SCBC) is an aggressive subtype that microscopically resembles aggressive small cell lung cancer (SCLC). This study confirms that SCBC shares DNA changes similar to SCLC and that SCBC expresses many genes that urothelial bladder cancer does not, possibly explaining aggressive SCBC activity.

来源:Eur Urol Oncol,查看原文。版权归原作者所有。

引用

  1. Hoffman-Censits J, Choi W, Pal S, et al. Urothelial Cancers with Small Cell Variant Histology Have Confirmed High Tumor Mutational Burden, Frequent TP53 and RB Mutations, and a Unique Gene Expression Profile. Eur Urol Oncol. 2020. PMID: 32061548. doi:10.1016/j.euo.2019.12.002

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。